← Back to Search

Ketorolac for Ovarian Cancer

Waitlist Available
Led By Carolyn Y. Muller, MD
Research Sponsored by New Mexico Cancer Care Alliance
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgery
Borderline ovarian cancer with ascites is allowable
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years following first ketorolac treatment
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Study Summary

This trial is testing whether ketorolac can help treat ovarian cancer by looking at how it affects cancer cells in the body.

Who is the study for?
This trial is for women over 18 with suspected or confirmed ovarian, fallopian tube, or primary peritoneal cancer who are undergoing surgery. They must be in good health otherwise, with no active bleeding, known bleeding disorders, peptic ulcers, allergies to NSAIDs like ibuprofen, and not taking other NSAIDs or anticoagulants around the time of surgery.Check my eligibility
What is being tested?
The study tests if Ketorolac (a painkiller) can inhibit certain cellular activities linked to ovarian cancer growth when given after surgery. Patients will either receive Ketorolac or a placebo to see if there's a difference between the two groups.See study design
What are the potential side effects?
Ketorolac may cause side effects such as stomach pain and ulcers, heartburn, nausea, vomiting; it can also increase the risk of bleeding. It might affect kidney function and could lead to allergic reactions in those sensitive to NSAIDs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am suspected to have ovarian, fallopian tube, or peritoneal cancer and am planning to undergo surgery to remove it.
I have borderline ovarian cancer with fluid in my abdomen.
I am mostly self-sufficient and can carry out daily activities.
I am a woman aged 18 or older.
My blood tests show enough neutrophils and platelets.
My liver tests are within the required range.
I do not have any known bleeding disorders.
I do not have an active stomach ulcer.
I am not currently experiencing any bleeding.
My cancer diagnosis was confirmed during surgery.
I had surgery to remove as much cancer as possible.
I am not experiencing any bleeding after surgery.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years following first ketorolac treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years following first ketorolac treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ketorolac inhibition of GTPase activity
Secondary outcome measures
Intraperitoneal and serum pharmacokinetics of ketorolac
Time to CA-125 normalization
Toxicity assessment
Other outcome measures
Overall survival (Exploratory objective)
Progression free survival (Exploratory objective)

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: KetorolacExperimental Treatment1 Intervention
Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
Group II: PlaceboPlacebo Group1 Intervention
Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Find a Location

Who is running the clinical trial?

New Mexico Cancer Care AllianceLead Sponsor
70 Previous Clinical Trials
52,446 Total Patients Enrolled
8 Trials studying Ovarian Cancer
254 Patients Enrolled for Ovarian Cancer
Carolyn Y. Muller, MDPrincipal InvestigatorUniversity of New Mexico Comprehensive Cancer Center
1 Previous Clinical Trials
1 Trials studying Ovarian Cancer

Media Library

Ketorolac Clinical Trial Eligibility Overview. Trial Name: NCT02470299 — N/A
Ovarian Cancer Research Study Groups: Ketorolac, Placebo
Ovarian Cancer Clinical Trial 2023: Ketorolac Highlights & Side Effects. Trial Name: NCT02470299 — N/A
Ketorolac 2023 Treatment Timeline for Medical Study. Trial Name: NCT02470299 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What ailments has Ketorolac been demonstrated to alleviate?

"Ketorolac is typically prescribed to treat ocular itching, but can also provide relief from pain and be administered as a nerve block or pupil dilation."

Answered by AI

Could you outline any prior research involving the use of Ketorolac?

"At the moment, 38 studies related to Ketorolac are underway. 8 of those projects occupy Phase 3 and 57 trial sites exist across the United States - with a hefty concentration in Los Angeles."

Answered by AI

To what extent has recruitment progressed for this study?

"Regrettably, this trial is not currently recruiting. It was inaugurated on October 29th 2015 and modified most recently on the 4th of October 2022. However, there are 697 fallopian tubes cancer clinical trials with open recruitment and 38 studies for Ketorolac that require participants."

Answered by AI

Is enrollment in this experiment still open to the public?

"According to records hosted on clinicaltrials.gov, the recruiting period for this medical research has concluded. This study debuted on October 29th 2015 and had its most recent update done in October 4th 2022. Despite the fact that patients are no longer being accepted, 735 other studies are still inviting participants right now."

Answered by AI
~2 spots leftby Feb 2025